JPRN-UMIN000000965已完成未知
Phase 2 study of cisplatin and pemetrexed in previously treated patients with malignant pleural mesothelioma - Phase 2 study of cisplatin and pemetrexed in previously treated patients with malignant pleural mesothelioma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Serious or uncontrolled complication 2. Active infection 3. Active concomitant malignancy 4. Symptomatic brain metastasis 5. With prior unapproved drugs or investigational new drugs 6. With a history of sensitivity to platinum agent, folic acid or vitamin B12 7. Women with confirmed, lactating or suspected pregnancy. Patients who won't avoid pregnancy. 8. Peripheral neuropathy >= grade 2 9. Interstitial pneumonia or fibroid lung 10. Medically endorsed anticonception can't be assured till 90 days after the final administration 11. Inappropriate patients for entry on this trial in the judgment of the investigator.
研究者
相似试验
已完成
2 期
A phase 2 study of cisplatin/pemetrexed followed by maintenance pemetrexed in patients with stage 3B or 4 non-squamous non-small-cell lung cancer.Previously untreated stageIIIB/IV non-squamous non-small-cell lung cancerJPRN-UMIN000002686Kinki-chuo chest medical center35
进行中（未招募）
不适用
Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study) - SoMe Studymalignant pleural mesothelioma (MPM)MedDRA version: 9.1Level: LLTClassification code 10059518Term: Pleural mesothelioma malignantEUCTR2007-005894-77-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
进行中（未招募）
不适用
A Phase II Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055MedDRA version: 9.1Level: LLTClassification code 10025054EUCTR2008-004330-24-ITEli Lilly and Company125
进行中（未招募）
1 期
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-NLEli Lilly and Company113
进行中（未招募）
不适用
A Phase 2 Study of Pemetrexed and Cisplatin plus Cetuximab followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell Histology - S104ocally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) other than Predominantly Squamous Cell HistologyMedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVMedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBEUCTR2008-004330-24-DEEli Lilly and Company125